​

ImmunityBio (IBRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IBRX Stock Forecast

ImmunityBio (IBRX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a 12.72% increase from the last price of $6.21.

$2 $3 $4 $5 $6 $7 $8 High: $7 Avg: $7 Low: $7 Last Closed Price: $6.21

IBRX Stock Rating

ImmunityBio stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

IBRX Price Target Upside V Benchmarks

TypeNameUpside
StockImmunityBio12.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$7.00$7.00$7.00
Last Closing Price$6.21$6.21$6.21
Upside/Downside12.72%12.72%12.72%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2614---5
Dec, 2514---5
Nov, 2523---5
Oct, 2523---5
Sep, 2523---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 20, 2026Piper Sandler$7.00$5.5226.81%12.72%
Jan 10, 2025Justin ZelinBTIG$6.00$2.42147.93%-3.38%
Aug 03, 2022Kelly ShiJefferies$8.00$4.1393.70%28.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 22, 2026BTIGBuyBuyhold
Jan 20, 2026AldenOverweightOverweighthold
Jan 20, 2026Piper SandlerOverweightOverweighthold
Dec 12, 2025JefferiesBuyBuyhold
May 20, 2025Piper SandlerOverweightupgrade
May 05, 2025H.C. WainwrightBuyBuyhold
Mar 06, 2025H.C. WainwrightBuyinitialise
Jan 10, 2025BTIGBuyinitialise
Oct 23, 2024EF HuttonBuyinitialise
Apr 26, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.90$-1.04$-1.15$-0.59----
Avg Forecast$-1.35$-1.00$-0.93$-0.81$-0.67$-0.35$0.33$1.25
High Forecast$-1.22$-0.81$-0.75$-0.60$-0.48$-0.15$1.47$1.54
Low Forecast$-1.48$-1.26$-1.14$-1.01$-0.85$-0.55$-0.37$1.01
Surprise %-33.33%4.00%23.66%-27.16%----

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$934.00K$240.00K$622.00K$14.74M----
Avg Forecast$569.00K$192.00K$508.00K$21.23M$136.22M$330.78M$974.18M$2.23B
High Forecast$609.74K$230.45K$597.39K$21.66M$148.00M$330.78M$1.15B$2.62B
Low Forecast$528.26K$164.18K$433.60K$20.79M$124.45M$330.78M$831.51M$1.90B
Surprise %64.15%25.00%22.44%-30.53%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-349.85M$-417.32M$-583.20M$-413.56M----
Avg Forecast$-686.66M$-508.64M$-482.11M$-407.23M$-338.68M$-201.94M$147.27M$635.97M
High Forecast$-622.75M$-412.84M$-382.97M$-302.64M$-244.02M$-76.16M$750.18M$781.46M
Low Forecast$-750.56M$-641.06M$-581.24M$-511.81M$-433.35M$-279.27M$-190.18M$514.89M
Surprise %-49.05%-17.95%20.97%1.56%----

IBRX Forecast FAQ

Is ImmunityBio stock a buy?

ImmunityBio stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ImmunityBio is a favorable investment for most analysts.

What is ImmunityBio's price target?

ImmunityBio's price target, set by 5 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential 12.72% change from the previous closing price of $6.21.

How does ImmunityBio stock forecast compare to its benchmarks?

ImmunityBio's stock forecast shows a 12.72% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ImmunityBio over the past three months?

  • January 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ImmunityBio’s EPS forecast?

ImmunityBio's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.67, marking a 13.56% increase from the reported $-0.59 in 2024. Estimates for the following years are $-0.35 in 2026, $0.33 in 2027, and $1.25 in 2028.

What is ImmunityBio’s revenue forecast?

ImmunityBio's average annual revenue forecast for its fiscal year ending in December 2025 is $136.22M, reflecting a 823.87% increase from the reported $14.74M in 2024. The forecast for 2026 is $330.78M, followed by $974.18M for 2027, and $2.23B for 2028.

What is ImmunityBio’s net income forecast?

ImmunityBio's net income forecast for the fiscal year ending in December 2025 stands at $-339M, representing a -18.11% decrease from the reported $-414M in 2024. Projections indicate $-202M in 2026, $147.27M in 2027, and $635.97M in 2028.